Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an ongoing global pandemic of
COVID-19. It has been found that
COVID-19 has an influence on the changes of blood coagulation parameters and the high incidence of
thrombosis. Changchun experienced the epidemic of the Omicron
BA.2 variant SARS-CoV-2 in March 2022 in China. Once infected,
BA.2 spreads rapidly and most of them are asymptomatic. The purpose of this study is to research
venous thrombosis and laboratory changes (including PLT, PT, APTT, DD,
FDP, CRP, WBC, IL-6 and lymphocyte subsets) among 92
cancer patients with
COVID-19 and 73
COVID-19 patients with non-
cancer by Mann-Whitney U and Chi-square test. It was found that the levels of
D-dimer,
FDP, CRP and
IL-6 in
cancer patients were significantly higher than those in the
COVID-19 cohort. There were 9 (9.8%)
cancer patients and 2 (2.7%) non-
cancer patients found VTE, with no significant difference. The results showed that WBC, lymphocytes and B cells in
cancer patients were significantly lower than those in the other group. Prophylactic anticoagulation was recommended for
cancer patients with high risk factors, while paying attention to the occurrence of
bleeding events. The detection of leukocyte classification,
D-dimer, prothrombin time and
fibrinogen at different time points are helpful for the diagnosis and anticoagulation of
COVID-19 patients with
cancer.